180 Life Sciences Stock Current Asset
| ATNF Stock | USD 2.25 0.03 1.32% |
180 Life Sciences fundamentals help investors to digest information that contributes to 180 Life's financial success or failures. It also enables traders to predict the movement of 180 Stock. The fundamental analysis module provides a way to measure 180 Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to 180 Life stock.
The 180 Life's current Total Current Assets is estimated to increase to about 4 M, while Non Current Assets Total are projected to decrease to roughly 1.5 M. 180 | Current Asset |
180 Life Sciences Company Current Asset Analysis
180 Life's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
180 Current Asset Historical Pattern
Today, most investors in 180 Life Stock are looking for potential investment opportunities by analyzing not only static indicators but also various 180 Life's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of 180 Life current asset as a starting point in their analysis.
180 Life Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
180 Total Assets
Total Assets |
|
In accordance with the recently published financial statements, 180 Life Sciences has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
180 Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 180 Life's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 180 Life could also be used in its relative valuation, which is a method of valuing 180 Life by comparing valuation metrics of similar companies.180 Life is currently under evaluation in current asset category among its peers.
180 Life ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, 180 Life's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to 180 Life's managers, analysts, and investors.Environmental | Governance | Social |
180 Fundamentals
| Return On Equity | -3.99 | ||||
| Return On Asset | -0.63 | ||||
| Current Valuation | 7.51 M | ||||
| Shares Outstanding | 1.98 M | ||||
| Shares Owned By Insiders | 4.34 % | ||||
| Shares Owned By Institutions | 3.45 % | ||||
| Number Of Shares Shorted | 139.43 K | ||||
| Price To Earning | 0.63 X | ||||
| Price To Book | 1.19 X | ||||
| EBITDA | (22.13 M) | ||||
| Net Income | (19.94 M) | ||||
| Cash And Equivalents | 1.63 M | ||||
| Cash Per Share | 0.04 X | ||||
| Total Debt | 1.05 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 0.67 X | ||||
| Book Value Per Share | (0.24) X | ||||
| Cash Flow From Operations | (10.92 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | 7.98 X | ||||
| Target Price | 80.0 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 4.45 M | ||||
| Total Asset | 5.26 M | ||||
| Retained Earnings | (127.34 M) | ||||
| Working Capital | (1.42 M) | ||||
| Net Asset | 5.26 M |
About 180 Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 180 Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 180 Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 180 Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether 180 Life Sciences is a strong investment it is important to analyze 180 Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 180 Life's future performance. For an informed investment choice regarding 180 Stock, refer to the following important reports:Check out 180 Life Piotroski F Score and 180 Life Altman Z Score analysis. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 180 Life. If investors know 180 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 180 Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 7.98 | Return On Assets (0.64) | Return On Equity (3.99) |
The market value of 180 Life Sciences is measured differently than its book value, which is the value of 180 that is recorded on the company's balance sheet. Investors also form their own opinion of 180 Life's value that differs from its market value or its book value, called intrinsic value, which is 180 Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 180 Life's market value can be influenced by many factors that don't directly affect 180 Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 180 Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if 180 Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 180 Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.